ç±³FDAãããã€ç
ãã«â1é±éã§å¹ãâå³å¹æ§ã®é£²ã¿è¬ãåæ¿èªâŠåé¡èŠãããŠããâäŸåæ§âã«ããå¶éããªã
8/30(ç«)
ã¢ã¡ãªã«é£åå»è¬åå±ïŒFDAïŒããæ©ããã°1é±éã§å¹ããšããæ°è¬ããªãŒãŽã§ãªãã£ãïŒAuvelityïŒããèšåºçãã€ç ã®æ²»çè¬ãšããŠæ¿èªããã
ã¢ã¯ãµã ã»ã»ã©ãã¥ãŒãã£ã¯ã¹ïŒAxsome TherapeuticsïŒãåºãããã®âå³å¹æ§âã®é£²ã¿è¬ã¯ãã¡ã³ã¿ã«ãã«ã¹æ²»çã®ããæ¹ãå€ããå¯èœæ§ãããã
FDAã«ããé©æ°çãªæ²»çè¬ã®éçºä¿é²ãç®çãšããå¶åºŠããã¬ã€ã¯ã¹ã«ãŒã»ã©ããŒæå®ãåããåããŠã®ã¿ã€ãã®è¬ã ã
ããªãŒãŽã§ãªãã£ãã¯N -ã¡ãã« -D -ã¢ã¹ãã©ã®ã³é žïŒNMDAïŒå容äœæ®æè¬ã§ãæ°ããã¿ã€ãã®ãã€ç æ²»çè¬ãæ¿èªãããã®ã¯ããã®60幎éã§åããŠã®ããšã ã
8/30(ç«)
ã¢ã¡ãªã«é£åå»è¬åå±ïŒFDAïŒããæ©ããã°1é±éã§å¹ããšããæ°è¬ããªãŒãŽã§ãªãã£ãïŒAuvelityïŒããèšåºçãã€ç ã®æ²»çè¬ãšããŠæ¿èªããã
ã¢ã¯ãµã ã»ã»ã©ãã¥ãŒãã£ã¯ã¹ïŒAxsome TherapeuticsïŒãåºãããã®âå³å¹æ§âã®é£²ã¿è¬ã¯ãã¡ã³ã¿ã«ãã«ã¹æ²»çã®ããæ¹ãå€ããå¯èœæ§ãããã
FDAã«ããé©æ°çãªæ²»çè¬ã®éçºä¿é²ãç®çãšããå¶åºŠããã¬ã€ã¯ã¹ã«ãŒã»ã©ããŒæå®ãåããåããŠã®ã¿ã€ãã®è¬ã ã
ããªãŒãŽã§ãªãã£ãã¯N -ã¡ãã« -D -ã¢ã¹ãã©ã®ã³é žïŒNMDAïŒå容äœæ®æè¬ã§ãæ°ããã¿ã€ãã®ãã€ç æ²»çè¬ãæ¿èªãããã®ã¯ããã®60幎éã§åããŠã®ããšã ã